Brief: Eagle Pharmaceuticals Reports Q4 Adjusted EPS Of $1.10

Eagle Pharmaceuticals

13/03/2023 10:59

March 13 (Reuters) - Eagle Pharmaceuticals Inc  EGRX.O :
    * EAGLE PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR
2022
RESULTS
    * Q4 2022 NET INCOME WAS $8.2 MILLION, OR $0.63 PER BASIC
AND
$0.62 PER DILUTED SHARE
    * EAGLE PHARMACEUTICALS - CASH AND CASH EQUIVALENTS WERE
$55.3
MILLION, NET ACCOUNTS RECEIVABLE WAS $72.4 MILLION, TOTAL DEBT
WAS $63.8 MILLION, AS OF DEC 31, 2022
    * QTRLY EPS $0.62
    * HOLDS LESS THAN $1.0 MILLION IN CASH AND CASH EQUIVALENTS
AT
SILICON VALLEY BANK
    * QTRLY NON-GAAP EPS $1.10
    * SEES 2023 ADJUSTED NON-GAAP EARNINGS PER SHARE OF
$4.20-$4.53
    * SEES 2023 ADJUSTED EBITDA OF $74.0-$80.0 MILLION
    * Q4 EARNINGS PER SHARE VIEW $0.83, REVENUE VIEW $64.3
MILLION --
REFINITIV IBES DATA
    * FY2023 EARNINGS PER SHARE VIEW $4.49, REVENUE VIEW $271.4
MILLION -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX2r6GVH 
Further company coverage:  EGRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))